v3.26.1
ACQUISITION
12 Months Ended
Dec. 31, 2025
Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation [Abstract]  
ACQUISITION

NOTE 12 – ACQUISITION

 

On October 11, 2024, Renu Laboratories LLC (a wholly owned subsidiary of myLife Wellness Company which is a wholly owned subsidiary of Investview, Inc.) closed on the purchase of the business and assets of Renu Labs, Inc. (“Seller”), along with a 100% ownership interest in Goldman’s Pharmaceuticals LLC and a 50% ownership interest in ELRT Technologies, LLC (together known as “Renu Labs”) from Gregg Hanson. Renu Labs is a manufacturer of proprietary and other health, beauty, and wellness products. The total purchase price of Renu Labs was $1,780,000.

 

The transaction was accounted for as a business combination using the acquisition method of accounting in accordance with the ASC Topic 805. The following table summarizes the purchase accounting for the fair value of the assets acquired and liabilities assumed at the date of the acquisition:

 

      
Cash  $1,495 
Customer deposits – intercompany   7,360 
Domain names [1]   40,310 
Raw materials   149,260 
Manufacturing equipment   717,020 
Total assets acquired  $915,445 
      
Accounts payable  $323 
Customer deposits   572,386 
Total liabilities assumed  $572,709 
      
Net assets acquired   342,736 
      
Consideration [2]  $1,207,614 
Fair value of noncontrolling interest in ELRT Technologies, LLC   8,823 
Total   1,216,437 
      
Goodwill [3]  $873,701 

 

[1] Domain names were deemed to have an indefinite life; therefore, amounts are not amortized, but rather are assessed for impairment as further discussed in our impairment policy. During the year ended December 31, 2025, domain names were impaired $29,511.
   
[2] This amount is equal to the $1,780,000 purchase price less $572,386 of customer deposits collected by Renu Labs, Inc. prior to acquisition.
   
[3] During the year ended December 31, 2025, goodwill was fully impaired.

 

 

INVESTVIEW, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

DECEMBER 31, 2025 AND 2024